Paul F. Reid, Ph.D., is a Co-Founder and Chief Executive Officer of ReceptoPharm. Dr. Reid is equipped with a broad scientific background, encompassing 14+ years in clinical development and research, with a direct approach to moving products from preclinical into clinical phases. He has worked and negotiated with drug regulatory agencies in the US, Canada, EU, South America, South Africa, and China, enabling companies to move ahead, save millions on research and testing in clinical trials, and gain IND approvals. By leveraging his comprehensive understanding of regulatory requirements he can guide new projects through the correct protocols at a minimum budget, advancing products, positioning for licensing, and setting up manufacturing. The application of his knowledge of laboratory practices to select new technologies that enhance production, quality control, and product formats. Dr. Reid is a leading world expert in the therapeutic use of snake venom neurotoxins.
